Cellular and Molecular Targeted Drug Delivery in Central Nervous System Cancers: Advances in Targeting Strategies

Roth, G.A.; Abate, D.; Abate, K.H.; Abay, S.M.; Abbafati, C.; Abbasi, N.; Abbastabar, H.; Abd-Allah, F.; Abdela, J.; Abdelalim, A.; Abdollahpour, I.; Abdulkader, R.S.; Abebe, H.T.; Abebe, M.; Abebe, Z.; Abejie, A.N.; Abera, S.F.; Abil, O.Z.; Abraha, H.N.; Abrham, A.R.; Abu-Raddad, L.J.; Accrombessi, M.M.K.; Acharya, D.; Adamu, A.A.; Adebayo, O.M.; Adedoyin, R.A.; Adekanmbi, V.; Adetokunboh, O.O.; Adhena, B.M.; Adib, M.G.; Admasie, A.; Afshin, A.; Agarwal, G.; Agesa, K.M.; Agrawal, A.; Agrawal, S.; Ahmadi, A.; Ahmadi, M.; Ahmed, M.B.; Ahmed, S.; Aichour, A.N.; Aichour, I.; Aichour, M.T.E.; Akbari, M.E.; Akinyemi, R.O.; Akseer, N.; Al-Aly, Z.; Al-Eyadhy, A.; Al-Raddadi, R.M.; Alahdab, F.; Alam, K.; Alam, T.; Alebel, A.; Alene, K.A.; Alijanzadeh, M.; Alizadeh-Navaei, R.; Aljunid, S.M.; Alkerwi, A.; Alla, F.; Allebeck, P.; Alonso, J.; Altirkawi, K.; Alvis-Guzman, N.; Amare, A.T.; Aminde, L.N.; Amini, E.; Ammar, W.; Amoako, Y.A.; Anber, N.H.; Andrei, C.L.; Androudi, S.; Animut, M.D.; Anjomshoa, M.; Ansari, H.; Ansha, M.G.; Antonio, C.A.T.; Anwari, P.; Aremu, O.; Ärnlöv, J.; Arora, A.; Arora, M.; Artaman, A.; Aryal, K.K.; Asayesh, H.; Asfaw, E.T.; Ataro, Z.; Atique, S.; Atre, S.R.; Ausloos, M.; Avokpaho, E.F.G.A.; Awasthi, A.; Quintanilla, B.P.A.; Ayele, Y.; Ayer, R.; Azzopardi, P.S.; Babazadeh, A.; Bacha, U.; Badali, H.; Badawi, A.; Bali, A.G.; Ballesteros, K.E.; Banach, M.; Banerjee, K.; Bannick, M.S.; Banoub, J.A.M.; Barboza, M.A.; Barker-Collo, S.L.; Bärnighausen, T.W.; Barquera, S.; Barrero, L.H.; Bassat, Q.; Basu, S.; Baune, B.T.; Baynes, H.W.; Bazargan-Hejazi, S.; Bedi, N.; Beghi, E.; Behzadifar, M.; Behzadifar, M.; Béjot, Y.; Bekele, B.B.; Belachew, A.B.; Belay, E.; Belay, Y.A.; Bell, M.L.; Bello, A.K.; Bennett, D.A.; Bensenor, I.M.; Berman, A.E.; Bernabe, E.; Bernstein, R.S.; Bertolacci, G.J.; Beuran, M.; Beyranvand, T.; Bhalla, A.; Bhattarai, S.; Bhaumik, S.; Bhutta, Z.A.; Biadgo, B.; Biehl, M.H.; Bijani, A.; Bikbov, B.; Bilano, V.; Bililign, N.; Bin Sayeed, M.S.; Bisanzio, D.; Biswas, T.; Blacker, B.F.; Basara, B.B.; Borschmann, R.; Bosetti, C.; Bozorgmehr, K.; Brady, O.J.; Brant, L.C.; Brayne, C.; Brazinova, A.; Breitborde, N.J.K.; Brenner, H.; Briant, P.S.; Britton, G.; Brugha, T.; Busse, R.; Butt, Z.A.; Callender, C.S.K.H.; Campos-Nonato, I.R.; Campuzano Rincon, J.C.; Cano, J.; Car, M.; Cárdenas, R.; Carreras, G.; Carrero, J.J.; Carter, A.; Carvalho, F.; Castañeda-Orjuela, C.A.; Castillo Rivas, J.; Castle, C.D.; Castro, C.; Castro, F.; Catalá-López, F.; Cerin, E.; Chaiah, Y.; Chang, J-C.; Charlson, F.J.; Chaturvedi, P.; Chiang, P.P-C.; Chimed-Ochir, O.; Chisumpa, V.H.; Chitheer, A.; Chowdhury, R.; Christensen, H.; Christopher, D.J.; Chung, S-C.; Cicuttini, F.M.; Ciobanu, L.G.; Cirillo, M.; Cohen, A.J.; Cooper, L.T.; Cortesi, P.A.; Cortinovis, M.; Cousin, E.; Cowie, B.C.; Criqui, M.H.; Cromwell, E.A.; Crowe, C.S.; Crump, J.A.; Cunningham, M.; Daba, A.K.; Dadi, A.F.; Dandona, L.; Dandona, R.; Dang, A.K.; Dargan, P.I.; Daryani, A.; Das, S.K.; Das Gupta, R.; Das Neves, J.; Dasa, T.T.; Dash, A.P.; Davis, A.C.; Davis Weaver, N.; Davitoiu, D.V.; Davletov, K.; De La Hoz, F.P.; De Neve, J-W.; Degefa, M.G.; Degenhardt, L.; Degfie, T.T.; Deiparine, S.; Demoz, G.T.; Demtsu, B.B.; Denova-Gutiérrez, E.; Deribe, K.; Dervenis, N.; Des Jarlais, D.C.; Dessie, G.A.; Dey, S.; Dharmaratne, S.D.; Dicker, D.; Dinberu, M.T.; Ding, E.L.; Dirac, M.A.; Djalalinia, S.; Dokova, K.; Doku, D.T.; Donnelly, C.A.; Dorsey, E.R.; Doshi, P.P.; Douwes-Schultz, D.; Doyle, K.E.; Driscoll, T.R.; Dubey, M.; Dubljanin, E.; Duken, E.E.; Duncan, B.B.; Duraes, A.R.; Ebrahimi, H.; Ebrahimpour, S.; Edessa, D.; Edvardsson, D.; Eggen, A.E.; El Bcheraoui, C.; El Sayed Zaki, M.; El-Khatib, Z.; Elkout, H.; Ellingsen, C.L.; Endres, M.; Endries, A.Y.; Er, B.; Erskine, H.E.; Eshrati, B.; Eskandarieh, S.; Esmaeili, R.; Esteghamati, A.; Fakhar, M.; Fakhim, H.; Faramarzi, M.; Fareed, M.; Farhadi, F.; Farinha, C.S.E. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the global burden of disease study 2017. Lancet, 2018, 392, 1736-1788.
[http://dx.doi.org/10.1016/S0140-6736(18)32203-7]

Smith, M.A.; Reaman, G.H. Remaining challenges in childhood cancer and newer targeted therapeutics. Pediatr. Clin. North Am., 2015, 62(1), 301-312.
[http://dx.doi.org/10.1016/j.pcl.2014.09.018] [PMID: 25435124]

Perkins, A.; Liu, G. Primary brain tumors in adults: diagnosis and treatment. Am. Fam. Physician, 2016, 93(3), 211-217.
[PMID: 26926614]

Chinot, O.L.; Wick, W.; Mason, W.; Henriksson, R.; Saran, F.; Nishikawa, R.; Carpentier, A.F.; Hoang-Xuan, K.; Kavan, P.; Cernea, D.; Brandes, A.A.; Hilton, M.; Abrey, L.; Cloughesy, T. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N. Engl. J. Med., 2014, 370(8), 709-722.
[http://dx.doi.org/10.1056/NEJMoa1308345] [PMID: 24552318]

Aldape, K.; Brindle, K.M.; Chesler, L.; Chopra, R.; Gajjar, A.; Gilbert, M.R.; Gottardo, N.; Gutmann, D.H.; Hargrave, D.; Holland, E.C.; Jones, D.T.W.; Joyce, J.A.; Kearns, P.; Kieran, M.W.; Mellinghoff, I.K.; Merchant, M.; Pfister, S.M.; Pollard, S.M.; Ramaswamy, V.; Rich, J.N.; Robinson, G.W.; Rowitch, D.H.; Sampson, J.H.; Taylor, M.D.; Workman, P.; Gilbertson, R.J. Challenges to curing primary brain tumours. Nat. Rev. Clin. Oncol., 2019, 16(8), 509-520.
[http://dx.doi.org/10.1038/s41571-019-0177-5] [PMID: 30733593]

Peyrl, A.; Frischer, J.; Hainfellner, J.A.; Preusser, M.; Dieckmann, K.; Marosi, C. Brain tumors - other treatment modalities. Handb. Clin. Neurol., 2017, 145, 547-560.
[http://dx.doi.org/10.1016/B978-0-12-802395-2.00034-1] [PMID: 28987193]

Saraiva, C.; Praça, C.; Ferreira, R.; Santos, T.; Ferreira, L.; Bernardino, L. Nanoparticle-mediated brain drug delivery: Overcoming blood-brain barrier to treat neurodegenerative diseases. J. Control. Release, 2016, 235, 34-47.
[http://dx.doi.org/10.1016/j.jconrel.2016.05.044] [PMID: 27208862]

Gerstner, E.R.; Fine, R.L. Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J. Clin. Oncol., 2007, 25(16), 2306-2312.
[http://dx.doi.org/10.1200/JCO.2006.10.0677] [PMID: 17538177]

Kornblith, P.L.; Walker, M. Chemotherapy for malignant gliomas. J. Neurosurg., 1988, 68(1), 1-17.
[http://dx.doi.org/10.3171/jns.1988.68.1.0001] [PMID: 3275753]

GBD 2016 Neurology Collaborators, V.L.; Nichols, E.; Alam, T.; Bannick, M.S.; Beghi, E.; Blake, N.;Zandian, H.; Zare, Z.; Zhang, Y.; Zodpey, S.; Naghavi, M.; Murray, C.J.L.; Vos, T. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the global burden of disease Study. Lancet Neurol., 2019, 18, 459-480.

GBD 2016 Brain and Other CNS Cancer Collaborators, A.P.; Fisher, J.L.; Belachew, A.B.; Bijani, A.; Feigin, V.L.; Murray, C.J.L.; Fitzmaurice, C. Global, regional, and national burden of brain and other cns cancer, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol., 2019, 18, 376-393.

Kishore, M.; Abdulqader, A.T.; Shihab Ahmad, H.; Hanumantharao, Y. Anticancer and antibacterial potential of green silver nanoparticles synthesized from maytenus senegalensis (l.) leaf extract and their characterization. Drug Invent. Today, 2018, 10, 554-561.

Mohandas, R.; Gayathri, R.; Priya, V. Cancer nanotechnology: a review. Drug Invent. Today, 2018, 10, 2719-2726.

Yadollahpour, A. Magnetic nanoparticles in medicine: a review of synthesis methods and important characteristics. Orient. J. Chem., 2015, 31, 271-277.
[http://dx.doi.org/10.13005/ojc/31.Special-Issue1.33]

Ashida, R.; Kawabata, K. ichi; Maruoka, T.; Asami, R.; Yoshikawa, H.; Takakura, R.; Ioka, T.; Katayama, K.; Tanaka, S. New approach for local cancer treatment using pulsed high-intensity focused ultrasound and phase-change nanodroplets. J. Med. Ultrason., 2015, 42, 457-466.
[http://dx.doi.org/10.1007/s10396-015-0634-4]

Han, H.; Lee, H.; Kim, K.; Kim, H. Effect of high intensity focused ultrasound (HIFU) in conjunction with a nanomedicines-microbubble complex for enhanced drug delivery. J. Control. Release, 2017, 266, 75-86.
[http://dx.doi.org/10.1016/j.jconrel.2017.09.022] [PMID: 28928042]

Parodi, A.; Rudzińska, M.; Deviatkin, A.A.; Soond, S.M.; Baldin, A.V.; Zamyatnin, A.A., Jr Established and emerging strategies for drug delivery across the blood-brain barrier in brain cancer. Pharmaceutics, 2019, 11(5), 11.
[http://dx.doi.org/10.3390/pharmaceutics11050245] [PMID: 31137689]

Vogelbaum, M.A.; Brewer, C.; Barnett, G.H.; Mohammadi, A.M.; Peereboom, D.M.; Ahluwalia, M.S.; Gao, S. First-in-human evaluation of the Cleveland Multiport Catheter for convection-enhanced delivery of topotecan in recurrent high-grade glioma: results of pilot trial 1. J. Neurosurg., 2018, 130, 1-10.
[http://dx.doi.org/10.3171/2017.10.JNS171845] [PMID: 29652233]

Kamaly, N.; Xiao, Z.; Valencia, P.M.; Radovic-Moreno, A.F.; Farokhzad, O.C. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem. Soc. Rev., 2012, 41(7), 2971-3010.
[http://dx.doi.org/10.1039/c2cs15344k] [PMID: 22388185]

Patel, D.; Kell, A.; Simard, B.; Xiang, B.; Lin, H.Y.; Tian, G. The cell labeling efficacy, cytotoxicity and relaxivity of copper-activated MRI/PET imaging contrast agents. Biomaterials, 2011, 32(4), 1167-1176.
[http://dx.doi.org/10.1016/j.biomaterials.2010.10.013] [PMID: 21035183]

Yadollahpour, A.; Rashidi, S. Magnetic nanoparticles: a review of chemical and physical characteristics important in medical applications. Orient. J. Chem., 2015, 31, 25-30.
[http://dx.doi.org/10.13005/ojc/31.Special-Issue1.03]

Yadollahpour, A.; Jalilifar, M.; Rashidi, S. A review of the feasibility and clinical applications of magnetic nanoparticles as contrast agents in magnetic resonance imaging. Int. J. Pharm. Technol., 2016, 8, 14737-14748.

Banerjee, D.; Sengupta, S. Nanoparticles in cancer chemotherapy. Prog. Mol. Biol. Transl. Sci., 2011, 104, 489-507.
[http://dx.doi.org/10.1016/B978-0-12-416020-0.00012-7] [PMID: 22093227]

Sarafraz, M.; Heidari, M.; Bayat, A.; Hanafi, M.G.; Fahimi, A.; Farasat, M.; Saki, N.; Molaei, J. Role of HRCT imaging in predicting the visibility of round window (rw) on patients underwent cochlear implant surgery. Clin. Epidemiol. Glob. Health, 2020, 8, 432-436.
[http://dx.doi.org/10.1016/j.cegh.2019.10.003]

Chichieveishvili, N.; Khubulava, S.; Korsantiya, B.; Kristesashvili, G.; Pichhaia, G. The possibility of silver nanoparticle use in medicine. Drug Invent. Today, 2018, 10, 1222-1226.

Rezaee, Z.; Yadollahpour, A.; Bayati, V.; Negad Dehbashi, F.; Negad Dehbashi, F.; Dehbashi, F.N. Gold nanoparticles and electroporation impose both separate and synergistic radiosensitizing effects in HT-29 tumor cells: an in vitro study. Int. J. Nanomedicine, 2017, 12, 1431-1439.
[http://dx.doi.org/10.2147/IJN.S128996] [PMID: 28260889]

Ali, Y.; Zohre, R.; Mostafa, J.; Samaneh, R. Dye-doped fluorescent nanoparticles in molecular imaging: a review of recent advances and future opportunities. Material Science Research India, 2014, 11(2), 102-113.
[http://dx.doi.org/10.13005/msri/110203]

Yadollahpour, A.; Hosseini, S.A.A.; Jalilifar, M.; Rashidi, S.; Rai, B.M.M. Magnetic nanoparticle-based drug and gene delivery: a review of recent advances and clinical applications. Int. J. Pharm. Technol., 2016, 8, 11451-11466.

Yadollahpour, A.; Venkateshwarlu, G. Applications of gadolinium nanoparticles in magnetic resonance imaging: a review on recent advances in clinical imaging. Int. J. Pharm. Technol., 2016, 8, 11379-11393.

Du, Y.; Rajamanickam, K.; Stumpf, T.R.; Qin, Y.; McCulloch, H.; Yang, X.; Zhang, J.; Tsai, E.; Cao, X. Paramagnetic quantum dots as multimodal probes for potential applications in nervous system imaging. J. Inorg. Organomet. Polym. Mater., 2018, 28, 711-720.
[http://dx.doi.org/10.1007/s10904-017-0766-7]

Ali, Y.; Zohre, R.; Mostafa, J.; Samaneh, R. Applications of upconversion nanoparticles in molecular imaging: a review of recent advances and future opportunities. Biosci. Biotechnol. Res. Asia, 2015, 12, 131-140.
[http://dx.doi.org/10.13005/bbra/1615]

Subbiahdoss, G.; Sharifi, S.; Grijpma, D.W.; Laurent, S.; van der Mei, H.C.; Mahmoudi, M.; Busscher, H.J. Magnetic targeting of surface-modified superparamagnetic iron oxide nanoparticles yields antibacterial efficacy against biofilms of gentamicin-resistant staphylococci. Acta Biomater., 2012, 8(6), 2047-2055.
[http://dx.doi.org/10.1016/j.actbio.2012.03.002] [PMID: 22406508]

Mao, H.Y.; Laurent, S.; Chen, W.; Akhavan, O.; Imani, M.; Ashkarran, A.A.; Mahmoudi, M. Graphene: promises, facts, opportunities, and challenges in nanomedicine. Chem. Rev., 2013, 113(5), 3407-3424.
[http://dx.doi.org/10.1021/cr300335p] [PMID: 23452512]

Mangraviti, A.; Gullotti, D.; Tyler, B.; Brem, H. Nanobiotechnology-based delivery strategies: New frontiers in brain tumor targeted therapies. J. Control. Release, 2016, 240, 443-453.
[http://dx.doi.org/10.1016/j.jconrel.2016.03.031] [PMID: 27016141]

Koziara, J.M.; Lockman, P.R.; Allen, D.D.; Mumper, R.J. In situ blood-brain barrier transport of nanoparticles. Pharm. Res., 2003, 20(11), 1772-1778.
[http://dx.doi.org/10.1023/B:PHAM.0000003374.58641.62] [PMID: 14661921]

Sharma, G.; Sharma, A.R.; Lee, S-S.; Bhattacharya, M.; Nam, J-S.; Chakraborty, C. Advances in nanocarriers enabled brain targeted drug delivery across blood brain barrier. Int. J. Pharm., 2019, 559, 360-372.
[http://dx.doi.org/10.1016/j.ijpharm.2019.01.056] [PMID: 30721725]

Grabrucker, A.M.; Ruozi, B.; Belletti, D.; Pederzoli, F.; Forni, F.; Vandelli, M.A.; Tosi, G. Nanoparticle transport across the blood brain barrier. Tissue Barriers, 2016, 4(1), e1153568.
[http://dx.doi.org/10.1080/21688370.2016.1153568] [PMID: 27141426]

Halle, B.; Mongelard, K.; Poulsen, F.R. Convection-enhanced drug delivery for glioblastoma: a systematic review focused on methodological differences in the use of the convection-enhanced delivery method. Asian J. Neurosurg., 2019, 14(1), 5-14.
[http://dx.doi.org/10.4103/ajns.AJNS_302_17] [PMID: 30937002]

Raucher, D.; Dragojevic, S.; Ryu, J. Macromolecular drug carriers for targeted glioblastoma therapy: preclinical studies, challenges, and future perspectives. Front. Oncol., 2018, 8, 624.
[http://dx.doi.org/10.3389/fonc.2018.00624] [PMID: 30619758]

Sharif, Y.; Jumah, F.; Coplan, L.; Krosser, A.; Sharif, K.; Tubbs, R.S. Blood brain barrier: A review of its anatomy and physiology in health and disease. Clin. Anat., 2018, 31(6), 812-823.
[http://dx.doi.org/10.1002/ca.23083] [PMID: 29637627]

Arvanitis, C.D.; Askoxylakis, V.; Guo, Y.; Datta, M.; Kloepper, J.; Ferraro, G.B.; Bernabeu, M.O.; Fukumura, D.; McDannold, N.; Jain, R.K. Mechanisms of enhanced drug delivery in brain metastases with focused ultrasound-induced blood-tumor barrier disruption. Proc. Natl. Acad. Sci. USA, 2018, 115(37), E8717-E8726.
[http://dx.doi.org/10.1073/pnas.1807105115] [PMID: 30150398]

Armulik, A.; Genové, G.; Mäe, M.; Nisancioglu, M.H.; Wallgard, E.; Niaudet, C.; He, L.; Norlin, J.; Lindblom, P.; Strittmatter, K.; Johansson, B.R.; Betsholtz, C. Pericytes regulate the blood-brain barrier. Nature, 2010, 468(7323), 557-561.
[http://dx.doi.org/10.1038/nature09522] [PMID: 20944627]

Pardridge, W.M. Drug transport across the blood-brain barrier. J. Cereb. Blood Flow Metab., 2012, 32(11), 1959-1972.
[http://dx.doi.org/10.1038/jcbfm.2012.126] [PMID: 22929442]

Serlin, Y.; Shelef, I.; Knyazer, B.; Friedman, A. Anatomy and physiology of the blood-brain barrier. Semin. Cell Dev. Biol., 2015, 38, 2-6.
[http://dx.doi.org/10.1016/j.semcdb.2015.01.002] [PMID: 25681530]

Cardoso, F.L.; Brites, D.; Brito, M.A. Looking at the blood-brain barrier: molecular anatomy and possible investigation approaches. Brain Res. Brain Res. Rev., 2010, 64(2), 328-363.
[http://dx.doi.org/10.1016/j.brainresrev.2010.05.003] [PMID: 20685221]

Shi, M.; Sanche, L. Convection-enhanced delivery in malignant gliomas: a review of toxicity and efficacy. J. Oncol., 2019, 2019, 9342796.
[http://dx.doi.org/10.1155/2019/9342796] [PMID: 31428153]

Bonkowski, D.; Katyshev, V.; Balabanov, R.D.; Borisov, A.; Dore-Duffy, P. The CNS microvascular pericyte: pericyte-astrocyte crosstalk in the regulation of tissue survival. Fluids Barriers CNS, 2011, 8(1), 8.
[http://dx.doi.org/10.1186/2045-8118-8-8] [PMID: 21349156]

Cucullo, L.; Couraud, P-O.; Weksler, B.; Romero, I-A.; Hossain, M.; Rapp, E.; Janigro, D. Immortalized human brain endothelial cells and flow-based vascular modeling: a marriage of convenience for rational neurovascular studies. J. Cereb. Blood Flow Metab., 2008, 28(2), 312-328.
[http://dx.doi.org/10.1038/sj.jcbfm.9600525] [PMID: 17609686]

Boje, K.M.K. In vivo measurement of blood-brain barrier. Curr. Protocols Pharmacol., 2002, 7, 1-39.

Hanada, S.; Fujioka, K.; Inoue, Y.; Kanaya, F.; Manome, Y.; Yamamoto, K. Cell-based in vitro blood-brain barrier model can rapidly evaluate nanoparticles’ brain permeability in association with particle size and surface modification. Int. J. Mol. Sci., 2014, 15(2), 1812-1825.
[http://dx.doi.org/10.3390/ijms15021812] [PMID: 24469316]

Byrne, J.D.; Betancourt, T.; Brannon-Peppas, L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv. Drug Deliv. Rev., 2008, 60(15), 1615-1626.
[http://dx.doi.org/10.1016/j.addr.2008.08.005] [PMID: 18840489]

de Boer, A.G.; Gaillard, P.J. Drug targeting to the brain. Annu. Rev. Pharmacol. Toxicol., 2007, 47, 323-355.
[http://dx.doi.org/10.1146/annurev.pharmtox.47.120505.105237] [PMID: 16961459]

Burton, A.R.; Baquet, Z.; Eisenbarth, G.S.; Tisch, R.; Smeyne, R.; Workman, C.J.; Vignali, D.A.A. Central nervous system destruction mediated by glutamic acid decarboxylase-specific CD4+ T cells. J. Immunol., 2010, 184(9), 4863-4870.
[http://dx.doi.org/10.4049/jimmunol.0903728] [PMID: 20348424]

Petty, M.A.; Lo, E.H. Junctional complexes of the blood-brain barrier: permeability changes in neuroinflammation. Prog. Neurobiol., 2002, 68(5), 311-323.
[http://dx.doi.org/10.1016/S0301-0082(02)00128-4] [PMID: 12531232]

Campbell, H.K.; Maiers, J.L.; DeMali, K.A. Interplay between Tight Junctions &amp. Adherens Junctions. Exp. Cell Res., 2017, 358, 39-44.
[http://dx.doi.org/10.1016/j.yexcr.2017.03.061] [PMID: 28372972]

Kobayashi, T.; Ishida, T.; Okada, Y.; Ise, S.; Harashima, H.; Kiwada, H. Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells. Int. J. Pharm., 2007, 329(1-2), 94-102.
[http://dx.doi.org/10.1016/j.ijpharm.2006.08.039] [PMID: 16997518]

Bretscher, A.; Edwards, K.; Fehon, R.G. ERM proteins and merlin: integrators at the cell cortex. Nat. Rev. Mol. Cell Biol., 2002, 3(8), 586-599.
[http://dx.doi.org/10.1038/nrm882] [PMID: 12154370]

Greish, K. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J. Drug Target., 2007, 15(7-8), 457-464.
[http://dx.doi.org/10.1080/10611860701539584] [PMID: 17671892]

Hu, Q.; Sun, W.; Wang, C.; Gu, Z. Recent advances of cocktail chemotherapy by combination drug delivery systems. Adv. Drug Deliv. Rev., 2016, 98, 19-34.
[http://dx.doi.org/10.1016/j.addr.2015.10.022] [PMID: 26546751]

Lakshmi, P.J.; Anitha, R.; Lakshmi, T. Targeted drug delivery systems used in dentistry - a short review. Drug Invent. Today, 2018, 10, 2747-2751.

Durairaj, B.; Santhi, R.; Hemalatha, A. Isolation of chitosan from fish scales of catla catla and synthesis, characterization and screening for larvicidal potential of chitosan-based silver nanoparticles. Drug Invent. Today, 2018, 10, 1357-1362.

Phillips, M.A.; Gran, M.L.; Peppas, N.A. Targeted nanodelivery of drugs and diagnostics. Nano Today, 2010, 5(2), 143-159.
[http://dx.doi.org/10.1016/j.nantod.2010.03.003] [PMID: 20543895]

Girardin, F. Membrane transporter proteins: a challenge for CNS drug development. Dialogues Clin. Neurosci., 2006, 8(3), 311-321.
[PMID: 17117613]

Lin, L.; Yee, S.W.; Kim, R.B.; Giacomini, K.M. SLC transporters as therapeutic targets: emerging opportunities. Nat. Rev. Drug Discov., 2015, 14(8), 543-560.
[http://dx.doi.org/10.1038/nrd4626] [PMID: 26111766]

Borst, P.; Elferink, R.O. Mammalian ABC transporters in health and disease. Annu. Rev. Biochem., 2002, 71, 537-592.
[http://dx.doi.org/10.1146/annurev.biochem.71.102301.093055] [PMID: 12045106]

Abbruscato, T.J.; Lopez, S.P.; Mark, K.S.; Hawkins, B.T.; Davis, T.P. Nicotine and cotinine modulate cerebral microvascular permeability and protein expression of ZO-1 through nicotinic acetylcholine receptors expressed on brain endothelial cells. J. Pharm. Sci., 2002, 91(12), 2525-2538.
[http://dx.doi.org/10.1002/jps.10256] [PMID: 12434396]

Choi, Y.H.; Yu, A-M. ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. Curr. Pharm. Des., 2014, 20(5), 793-807.
[http://dx.doi.org/10.2174/138161282005140214165212] [PMID: 23688078]

Zhan, C.; Lu, W. The blood-brain/tumor barriers: challenges and chances for malignant gliomas targeted drug delivery. Curr. Pharm. Biotechnol., 2012, 13(12), 2380-2387.
[http://dx.doi.org/10.2174/138920112803341798] [PMID: 23016643]

Hervé, F.; Ghinea, N.; Scherrmann, J-M. CNS delivery via adsorptive transcytosis. AAPS J., 2008, 10(3), 455-472.
[http://dx.doi.org/10.1208/s12248-008-9055-2] [PMID: 18726697]

Amin, M.L. P-glycoprotein inhibition for optimal drug delivery. Drug Target Insights, 2013, 7, 27-34.
[http://dx.doi.org/10.4137/DTI.S12519] [PMID: 24023511]

Mei, L.; Zhang, Z.; Zhao, L.; Huang, L.; Yang, X.L.; Tang, J.; Feng, S.S. Pharmaceutical nanotechnology for oral delivery of anticancer drugs. Adv. Drug Deliv. Rev., 2013, 65(6), 880-890.
[http://dx.doi.org/10.1016/j.addr.2012.11.005] [PMID: 23220325]

Culot, M.; Lundquist, S.; Vanuxeem, D.; Nion, S.; Landry, C.; Delplace, Y.; Dehouck, M.P.; Berezowski, V.; Fenart, L.; Cecchelli, R. An in vitro blood-brain barrier model for high throughput (hts) toxicological screening. Toxicol. In Vitro, 2008, 22(3), 799-811.
[http://dx.doi.org/10.1016/j.tiv.2007.12.016] [PMID: 18280105]

Song, W.; Li, D.; Tao, L.; Luo, Q.; Chen, L. Solute carrier transporters: the metabolic gatekeepers of immune cells. Acta Pharm. Sin. B, 2020, 10(1), 61-78.
[http://dx.doi.org/10.1016/j.apsb.2019.12.006] [PMID: 31993307]

Sabharanjak, S.; Mayor, S. Folate receptor endocytosis and trafficking. Adv. Drug Deliv. Rev., 2004, 56(8), 1099-1109.
[http://dx.doi.org/10.1016/j.addr.2004.01.010] [PMID: 15094209]

Bogman, K.; Erne-Brand, F.; Alsenz, J.; Drewe, J. The role of surfactants in the reversal of active transport mediated by multidrug resistance proteins. J. Pharm. Sci., 2003, 92(6), 1250-1261.
[http://dx.doi.org/10.1002/jps.10395] [PMID: 12761814]

Alexander, S.; Mathie, A.; Peters, J. Transporters are an under-developed therapeutic target. Discuss. Br. J. Pharmacol., 2011, 164(7), 1751-1752.
[http://dx.doi.org/10.1111/j.1476-5381.2011.01738.x] [PMID: 22085158]

Torchilin, V.P. Passive and active drug targeting: drug delivery to tumors as an example. In: Handbook of experimental pharmacology; Springer: Berlin; , 2010; pp. 3-53.

Bertrand, N.; Wu, J.; Xu, X.; Kamaly, N.; Farokhzad, O.C. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv. Drug Deliv. Rev., 2014, 66, 2-25.
[http://dx.doi.org/10.1016/j.addr.2013.11.009] [PMID: 24270007]

Park, J.W.; Hong, K.; Kirpotin, D.B.; Colbern, G.; Shalaby, R.; Baselga, J.; Shao, Y.; Nielsen, U.B.; Marks, J.D.; Moore, D.; Papahadjopoulos, D.; Benz, C.C. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin. Cancer Res., 2002, 8(4), 1172-1181.
[PMID: 11948130]

Velraj, M.; Shruthi, V.; Murugavel, S.; Shanmugam, R. Evaluation of quercetin-loaded poly-lactide-co-glycolide acid silver nanoparticles from the ethanolic extract of mallotus philippensis fruits. Drug Invent. Today, 2018, 10, 253-256.

Drummond, D.C.; Hong, K.; Park, J.W.; Benz, C.C.; Kirpotin, D.B. Liposome targeting to tumors using vitamin and growth factor receptors. Vitam. Horm., 2000, 60, 285-332.
[http://dx.doi.org/10.1016/S0083-6729(00)60022-5] [PMID: 11037627]

Adams, G.P.; Schier, R.; McCall, A.M.; Simmons, H.H.; Horak, E.M.; Alpaugh, R.K.; Marks, J.D.; Weiner, L.M. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res., 2001, 61(12), 4750-4755.
[PMID: 11406547]

Ventola, C.L. Progress in nanomedicine: approved and investigational nanodrugs. P&T, 2017, 42(12), 742-755.
[PMID: 29234213]

Maeda, H.; Matsumura, Y. Tumoritropic and lymphotropic principles of macromolecular drugs. Crit. Rev. Ther. Drug Carrier Syst., 1989, 6(3), 193-210.
[PMID: 2692843]

Peer, D.; Karp, J.M.; Hong, S.; Farokhzad, O.C.; Margalit, R.; Langer, R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol., 2007, 2(12), 751-760.
[http://dx.doi.org/10.1038/nnano.2007.387] [PMID: 18654426]

Bazak, R.; Houri, M.; Achy, S.E.; Hussein, W.; Refaat, T. Passive targeting of nanoparticles to cancer: A comprehensive review of the literature. Mol. Clin. Oncol., 2014, 2(6), 904-908.
[http://dx.doi.org/10.3892/mco.2014.356] [PMID: 25279172]

Brannon-Peppas, L.; Blanchette, J.O. Nanoparticle and targeted systems for cancer therapy. Adv. Drug Deliv. Rev., 2004, 56(11), 1649-1659.
[http://dx.doi.org/10.1016/j.addr.2004.02.014] [PMID: 15350294]

Kreuter, J. Nanoparticles--a historical perspective. Int. J. Pharm., 2007, 331(1), 1-10.
[http://dx.doi.org/10.1016/j.ijpharm.2006.10.021] [PMID: 17110063]

Bazak, R.; Houri, M.; El Achy, S.; Kamel, S.; Refaat, T. Cancer active targeting by nanoparticles: a comprehensive review of literature. J. Cancer Res. Clin. Oncol., 2015, 141(5), 769-784.
[http://dx.doi.org/10.1007/s00432-014-1767-3] [PMID: 25005786]

Sweetha, G.; Abraham, A.; Dhanraj, M.; Jain, A.R. Fabrication and evaluation of polylactic acid membrane for drug delivery system. Drug Invent. Today, 2018, 10, 433-436.

Brigger, I.; Dubernet, C.; Couvreur, P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev., 2002, 54(5), 631-651.
[http://dx.doi.org/10.1016/S0169-409X(02)00044-3] [PMID: 12204596]

Jones, A.; Harris, A.L. New developments in angiogenesis: a major mechanism for tumor growth and target for therapy. Cancer J. Sci. Am., 1998, 4(4), 209-217.
[PMID: 9689977]

Baban, D.F.; Seymour, L.W. Control of tumour vascular permeability. Adv. Drug Deliv. Rev., 1998, 34(1), 109-119.
[http://dx.doi.org/10.1016/S0169-409X(98)00003-9] [PMID: 10837673]

Segal, E.; Pan, H.; Ofek, P.; Udagawa, T.; Kopecková, P.; Kopecek, J.; Satchi-Fainaro, R. Targeting angiogenesis-dependent calcified neoplasms using combined polymer therapeutics. PLoS One, 2009, 4(4), e5233.
[http://dx.doi.org/10.1371/journal.pone.0005233] [PMID: 19381291]

Zhao, Y.; Adjei, A.A. Targeting angiogenesis in cancer therapy: moving beyond vascular endothelial growth factor. Oncologist, 2015, 20(6), 660-673.
[http://dx.doi.org/10.1634/theoncologist.2014-0465] [PMID: 26001391]

Hobbs, S.K.; Monsky, W.L.; Yuan, F.; Roberts, W.G.; Griffith, L.; Torchilin, V.P.; Jain, R.K. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl. Acad. Sci. USA, 1998, 95(8), 4607-4612.
[http://dx.doi.org/10.1073/pnas.95.8.4607] [PMID: 9539785]

Rubin, P.; Casarett, G. Microcirculation of tumors. II. The supervascularized state of irradiated regressing tumors. Clin. Radiol., 1966, 17(4), 346-355.
[http://dx.doi.org/10.1016/S0009-9260(66)80052-1] [PMID: 5924244]

Shubik, P. Vascularization of tumors: a review. J. Cancer Res. Clin. Oncol., 1982, 103(3), 211-226.
[http://dx.doi.org/10.1007/BF00409698] [PMID: 6181069]

Pérez-Herrero, E.; Fernández-Medarde, A. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. Eur. J. Pharm. Biopharm., 2015, 93, 52-79.
[http://dx.doi.org/10.1016/j.ejpb.2015.03.018] [PMID: 25813885]

Folkman, J.; Merler, E.; Abernathy, C.; Williams, G. Isolation of a tumor factor responsible for angiogenesis. J. Exp. Med., 1971, 133(2), 275-288.
[http://dx.doi.org/10.1084/jem.133.2.275] [PMID: 4332371]

Haibe, Y.; Kreidieh, M.; El Hajj, H.; Khalifeh, I.; Mukherji, D.; Temraz, S.; Shamseddine, A. Resistance mechanisms to anti-angiogenic therapies in cancer. Front. Oncol., 2020, 10, 221.
[http://dx.doi.org/10.3389/fonc.2020.00221] [PMID: 32175278]

Maeda, H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul., 2001, 41, 189-207.
[http://dx.doi.org/10.1016/S0065-2571(00)00013-3] [PMID: 11384745]

Veikkola, T.; Karkkainen, M.; Claesson-Welsh, L.; Alitalo, K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res., 2000, 60(2), 203-212.
[PMID: 10667560]

Haley, B.; Frenkel, E. Nanoparticles for drug delivery in cancer treatment. Urol. Oncol., 2008, 26(1), 57-64.
[http://dx.doi.org/10.1016/j.urolonc.2007.03.015] [PMID: 18190833]

Matsumura, Y.; Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res., 1986, 46(12 Pt 1), 6387-6392.
[PMID: 2946403]

Zhang, J.; Tang, H.; Liu, Z.; Chen, B. Effects of major parameters of nanoparticles on their physical and chemical properties and recent application of nanodrug delivery system in targeted chemotherapy. Int. J. Nanomedicine, 2017, 12, 8483-8493.
[http://dx.doi.org/10.2147/IJN.S148359] [PMID: 29238188]

Krasnici, S.; Werner, A.; Eichhorn, M.E.; Schmitt-Sody, M.; Pahernik, S.A.; Sauer, B.; Schulze, B.; Teifel, M.; Michaelis, U.; Naujoks, K.; Dellian, M. Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels. Int. J. Cancer, 2003, 105(4), 561-567.
[http://dx.doi.org/10.1002/ijc.11108] [PMID: 12712451]

Kunstfeld, R.; Wickenhauser, G.; Michaelis, U.; Teifel, M.; Umek, W.; Naujoks, K.; Wolff, K.; Petzelbauer, P. Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a “humanized” SCID mouse model. J. Invest. Dermatol., 2003, 120(3), 476-482.
[http://dx.doi.org/10.1046/j.1523-1747.2003.12057.x] [PMID: 12603862]

Thurston, G.; McLean, J.W.; Rizen, M.; Baluk, P.; Haskell, A.; Murphy, T.J.; Hanahan, D.; McDonald, D.M. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J. Clin. Invest., 1998, 101(7), 1401-1413.
[http://dx.doi.org/10.1172/JCI965] [PMID: 9525983]

Ran, S.; Downes, A.; Thorpe, P.E. Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res., 2002, 62(21), 6132-6140.
[PMID: 12414638]

Zhuang, J.; Gordon, M.R.; Ventura, J.; Li, L.; Thayumanavan, S. Multi-stimuli responsive macromolecules and their assemblies. Chem. Soc. Rev., 2013, 42(17), 7421-7435.
[http://dx.doi.org/10.1039/c3cs60094g] [PMID: 23765263]

Cheng, Y.; Zhao, L.; Li, Y.; Xu, T. Design of biocompatible dendrimers for cancer diagnosis and therapy: current status and future perspectives. Chem. Soc. Rev., 2011, 40(5), 2673-2703.
[http://dx.doi.org/10.1039/c0cs00097c] [PMID: 21286593]

Al-Ahmady, Z.; Kostarelos, K. Chemical components for the design of temperature-responsive vesicles as cancer therapeutics. Chem. Rev., 2016, 116(6), 3883-3918.
[http://dx.doi.org/10.1021/acs.chemrev.5b00578] [PMID: 26934630]

Mura, S.; Nicolas, J.; Couvreur, P. Stimuli-responsive nanocarriers for drug delivery. Nat. Mater., 2013, 12(11), 991-1003.
[http://dx.doi.org/10.1038/nmat3776] [PMID: 24150417]

Kiessling, F.; Mertens, M.E.; Grimm, J.; Lammers, T. Nanoparticles for imaging: top or flop? Radiology, 2014, 273(1), 10-28.
[http://dx.doi.org/10.1148/radiol.14131520] [PMID: 25247562]

Estrada, A.C.; Daniel-Da-Silva, A.L.; Trindade, T. Photothermally enhanced drug release by κ-carrageenan hydrogels reinforced with multi-walled carbon nanotubes. RSC Advances, 2013, 3, 10828-10836.
[http://dx.doi.org/10.1039/c3ra40662h]

Arranja, A.G.; Pathak, V.; Lammers, T.; Shi, Y. Tumor-targeted nanomedicines for cancer theranostics. Pharmacol. Res., 2017, 115, 87-95.
[http://dx.doi.org/10.1016/j.phrs.2016.11.014] [PMID: 27865762]

Gray, M.D.; Lyon, P.C.; Mannaris, C.; Folkes, L.K.; Stratford, M.; Campo, L.; Chung, D.Y.F.; Scott, S.; Anderson, M.; Goldin, R.; Carlisle, R.; Wu, F.; Middleton, M.R.; Gleeson, F.V.; Coussios, C.C. Focused ultrasound hyperthermia for targeted drug release from thermosensitive liposomes: results from a phase i trial. Radiology, 2019, 291(1), 232-238.
[http://dx.doi.org/10.1148/radiol.2018181445] [PMID: 30644817]

Oude Blenke, E.; Mastrobattista, E.; Schiffelers, R.M. Strategies for triggered drug release from tumor targeted liposomes. Expert Opin. Drug Deliv., 2013, 10(10), 1399-1410.
[http://dx.doi.org/10.1517/17425247.2013.805742] [PMID: 23796390]

van Elk, M.; Deckers, R.; Oerlemans, C.; Shi, Y.; Storm, G.; Vermonden, T.; Hennink, W.E. Triggered release of doxorubicin from temperature-sensitive poly(N-(2-hydroxypropyl)-methacrylamide mono/dilactate) grafted liposomes. Biomacromolecules, 2014, 15(3), 1002-1009.
[http://dx.doi.org/10.1021/bm401904u] [PMID: 24476227]

Zhang, Y.; Wei, C.; Lv, F.; Liu, T. Real-time imaging tracking of a dual-fluorescent drug delivery system based on doxorubicin-loaded globin- polyethylenimine nanoparticles for visible tumor therapy. Colloids Surf. B Biointerfaces, 2018, 170, 163-171.
[http://dx.doi.org/10.1016/j.colsurfb.2018.06.008] [PMID: 29906701]

Motamarry, A.; Negussie, A.H.; Rossmann, C.; Small, J.; Wolfe, A.M.; Wood, B.J.; Haemmerich, D. Real-time fluorescence imaging for visualization and drug uptake prediction during drug delivery by thermosensitive liposomes. Int. J. Hyperthermia, 2019, 36(1), 817-826.
[http://dx.doi.org/10.1080/02656736.2019.1642521] [PMID: 31451077]

Santos, M.A.; Goertz, D.E.; Hynynen, K. Focused ultrasound hyperthermia mediated drug delivery using thermosensitive liposomes and visualized with in vivo two-photon microscopy. Theranostics, 2017, 7(10), 2718-2731.
[http://dx.doi.org/10.7150/thno.19662] [PMID: 28819458]

Qian, Z.M.; Li, H.; Sun, H.; Ho, K. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol. Rev., 2002, 54(4), 561-587.
[http://dx.doi.org/10.1124/pr.54.4.561] [PMID: 12429868]

Gundelfinger, E.D.; Kessels, M.M.; Qualmann, B. Temporal and spatial coordination of exocytosis and endocytosis. Nat. Rev. Mol. Cell Biol., 2003, 4(2), 127-139.
[http://dx.doi.org/10.1038/nrm1016] [PMID: 12563290]

Etame, A.B.; Smith, C.A.; Chan, W.C.W.; Rutka, J.T. Design and potential application of PEGylated gold nanoparticles with size-dependent permeation through brain microvasculature. Nanomedicine (Lond.), 2011, 7(6), 992-1000.
[http://dx.doi.org/10.1016/j.nano.2011.04.004] [PMID: 21616168]

Decuzzi, P.; Godin, B.; Tanaka, T.; Lee, S.Y.; Chiappini, C.; Liu, X.; Ferrari, M. Size and shape effects in the biodistribution of intravascularly injected particles. J. Control. Release, 2010, 141(3), 320-327.
[http://dx.doi.org/10.1016/j.jconrel.2009.10.014] [PMID: 19874859]

Kolhar, P.; Anselmo, A.C.; Gupta, V.; Pant, K.; Prabhakarpandian, B.; Ruoslahti, E.; Mitragotri, S. Using shape effects to target antibody-coated nanoparticles to lung and brain endothelium. Proc. Natl. Acad. Sci. USA, 2013, 110(26), 10753-10758.
[http://dx.doi.org/10.1073/pnas.1308345110] [PMID: 23754411]

Lockman, P.R.; Koziara, J.M.; Mumper, R.J.; Allen, D.D. Nanoparticle surface charges alter blood-brain barrier integrity and permeability. J. Drug Target., 2004, 12(9-10), 635-641.
[http://dx.doi.org/10.1080/10611860400015936] [PMID: 15621689]

Kreuter, J.; Hekmatara, T.; Dreis, S.; Vogel, T.; Gelperina, S.; Langer, K. Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain. J. Control. Release, 2007, 118(1), 54-58.
[http://dx.doi.org/10.1016/j.jconrel.2006.12.012] [PMID: 17250920]

Bramini, M.; Ye, D.; Hallerbach, A.; Nic Raghnaill, M.; Salvati, A.; Åberg, C.; Dawson, K.A. Imaging approach to mechanistic study of nanoparticle interactions with the blood-brain barrier. ACS Nano, 2014, 8(5), 4304-4312.
[http://dx.doi.org/10.1021/nn5018523] [PMID: 24773217]

Choi, C.H.J.; Alabi, C.A.; Webster, P.; Davis, M.E. Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc. Natl. Acad. Sci. USA, 2010, 107(3), 1235-1240.
[http://dx.doi.org/10.1073/pnas.0914140107] [PMID: 20080552]

Wiley, D.T.; Webster, P.; Gale, A.; Davis, M.E. Transcytosis and brain uptake of transferrin-containing nanoparticles by tuning avidity to transferrin receptor. Proc. Natl. Acad. Sci. USA, 2013, 110(21), 8662-8667.
[http://dx.doi.org/10.1073/pnas.1307152110] [PMID: 23650374]

Huang, X.; Li, L.; Liu, T.; Hao, N.; Liu, H.; Chen, D.; Tang, F. The shape effect of mesoporous silica nanoparticles on biodistribution, clearance, and biocompatibility in vivo. ACS Nano, 2011, 5(7), 5390-5399.
[http://dx.doi.org/10.1021/nn200365a] [PMID: 21634407]

Jallouli, Y.; Paillard, A.; Chang, J.; Sevin, E.; Betbeder, D. Influence of surface charge and inner composition of porous nanoparticles to cross blood-brain barrier in vitro. Int. J. Pharm., 2007, 344(1-2), 103-109.
[http://dx.doi.org/10.1016/j.ijpharm.2007.06.023] [PMID: 17651930]

Gao, X.; Qian, J.; Zheng, S.; Changyi, Y.; Zhang, J.; Ju, S.; Zhu, J.; Li, C. Overcoming the blood-brain barrier for delivering drugs into the brain by using adenosine receptor nanoagonist. ACS Nano, 2014, 8(4), 3678-3689.
[http://dx.doi.org/10.1021/nn5003375] [PMID: 24673594]

Bellavance, M-A.; Blanchette, M.; Fortin, D. Recent advances in blood-brain barrier disruption as a CNS delivery strategy. AAPS J., 2008, 10(1), 166-177.
[http://dx.doi.org/10.1208/s12248-008-9018-7] [PMID: 18446517]

Donaldson, K.; Stone, V.; Clouter, A.; Renwick, L.; MacNee, W. Ultrafine particles. Occup. Environ. Med., 2001, 58(3), 211-216., 199.
[http://dx.doi.org/10.1136/oem.58.3.211] [PMID: 11171936]

Kumar, S.; Verma, M.K.; Srivastava, A.K. Ultrafine particles in urban ambient air and their health perspectives. Rev. Environ. Health, 2013, 28(2-3), 117-128.
[http://dx.doi.org/10.1515/reveh-2013-0008] [PMID: 24192498]

Frampton, M.W.; Rich, D.Q. Does particle size matter? ultrafine particles and hospital visits in eastern Europe. Am. J. Respir. Crit. Care Med., 2016, 194(10), 1180-1182.
[http://dx.doi.org/10.1164/rccm.201606-1164ED] [PMID: 27845588]

Morimoto, Y.; Kobayashi, N.; Shinohara, N.; Myojo, T.; Tanaka, I.; Nakanishi, J. Hazard assessments of manufactured nanomaterials. J. Occup. Health, 2010, 52(6)
[http://dx.doi.org/10.1539/joh.R10003]

Oberdörster, G.; Sharp, Z.; Atudorei, V.; Elder, A.; Gelein, R.; Kreyling, W.; Cox, C. Translocation of inhaled ultrafine particles to the brain. Inhal. Toxicol., 2004, 16(6-7), 437-445.
[http://dx.doi.org/10.1080/08958370490439597] [PMID: 15204759]

Nel, A.; Xia, T.; Mädler, L.; Li, N. Toxic potential of materials at the nanolevel. Science, 2006, 311(5761), 622-627.
[http://dx.doi.org/10.1126/science.1114397] [PMID: 16456071]

çetin, M.; Aytekin, E.; Yavuz, B.; Bozda-Pehlivan, S. Nanoscience in targeted brain drug delivery. In: Nanotechnology methods for neurological diseases and brain tumors: drug delivery across the blood-brain barrier; Elsevier: Amsterdam, 2017, 117-147.

Allen, J.L.; Liu, X.; Weston, D.; Prince, L.; Oberdörster, G.; Finkelstein, J.N.; Johnston, C.J.; Cory-Slechta, D.A. Developmental exposure to concentrated ambient ultrafine particulate matter air pollution in mice results in persistent and sex-dependent behavioral neurotoxicity and glial activation. Toxicol. Sci., 2014, 140(1), 160-178.
[http://dx.doi.org/10.1093/toxsci/kfu059] [PMID: 24690596]

Karmakar, A.; Zhang, Q.; Zhang, Y. Neurotoxicity of nanoscale materials. Yao Wu Shi Pin Fen Xi, 2014, 22(1), 147-160.
[http://dx.doi.org/10.1016/j.jfda.2014.01.012] [PMID: 24673911]

Pehlivan, S.B. Nanotechnology-based drug delivery systems for targeting, imaging and diagnosis of neurodegenerative diseases. Pharm. Res., 2013, 30(10), 2499-2511.
[http://dx.doi.org/10.1007/s11095-013-1156-7] [PMID: 23959851]

Matés, J.M.; Sánchez-Jiménez, F. Antioxidant enzymes and their implications in pathophysiologic processes. Front. Biosci., 1999, 15(4), D339-D345.

Aschberger, K.; Micheletti, C.; Sokull-Klüttgen, B.; Christensen, F.M. Analysis of currently available data for characterising the risk of engineered nanomaterials to the environment and human health--lessons learned from four case studies. Environ. Int., 2011, 37(6), 1143-1156.
[http://dx.doi.org/10.1016/j.envint.2011.02.005] [PMID: 21397332]

Chan, V.S.W. Nanomedicine: An unresolved regulatory issue. Regul. Toxicol. Pharmacol., 2006, 46(3), 218-224.
[http://dx.doi.org/10.1016/j.yrtph.2006.04.009] [PMID: 17081666]

Wang, J.; Sun, P.; Bao, Y.; Liu, J.; An, L. Cytotoxicity of single-walled carbon nanotubes on PC12 cells. Toxicol. In Vitro, 2011, 25(1), 242-250.
[http://dx.doi.org/10.1016/j.tiv.2010.11.010] [PMID: 21094249]

Pisanic, T.R., II; Blackwell, J.D.; Shubayev, V.I.; Fiñones, R.R.; Jin, S. Nanotoxicity of iron oxide nanoparticle internalization in growing neurons. Biomaterials, 2007, 28(16), 2572-2581.
[http://dx.doi.org/10.1016/j.biomaterials.2007.01.043] [PMID: 17320946]

Tin-Tin-Win-Shwe. Mitsushima, D.; Yamamoto, S.; Fukushima, A.; Funabashi, T.; Kobayashi, T.; Fujimaki, H. Changes in neurotransmitter levels and proinflammatory cytokine mRNA expressions in the mice olfactory bulb following nanoparticle exposure. Toxicol. Appl. Pharmacol., 2008, 226(2), 192-198.
[http://dx.doi.org/10.1016/j.taap.2007.09.009] [PMID: 17950771]

Zhang, Q.L.; Li, M.Q.; Ji, J.W.; Gao, F.P.; Bai, R.; Chen, C.Y.; Wang, Z.W.; Zhang, C.; Niu, Q. In vivo toxicity of nano-alumina on mice neurobehavioral profiles and the potential mechanisms. Int. J. Immunopathol. Pharmacol., 2011, 24(1)(Suppl.), 23S-29S.
[PMID: 21329562]

Zhang, Q.; Ding, Y.; He, K.; Li, H.; Gao, F.; Moehling, T.J.; Wu, X.; Duncan, J.; Niu, Q. Exposure to alumina nanoparticles in female mice during pregnancy induces neurodevelopmental toxicity in the offspring. Front. Pharmacol., 2018, 9, 253.
[http://dx.doi.org/10.3389/fphar.2018.00253] [PMID: 29615914]

Wu, J.; Wang, C.; Sun, J.; Xue, Y. Neurotoxicity of silica nanoparticles: brain localization and dopaminergic neurons damage pathways. ACS Nano, 2011, 5(6), 4476-4489.
[http://dx.doi.org/10.1021/nn103530b] [PMID: 21526751]

Jaganathan, H.; Godin, B. Biocompatibility assessment of Si-based nano- and micro-particles. Adv. Drug Deliv. Rev., 2012, 64(15), 1800-1819.
[http://dx.doi.org/10.1016/j.addr.2012.05.008] [PMID: 22634160]

Barenholz, Y. Doxil®--the first FDA-approved nano-drug: lessons learned. J. Control. Release, 2012, 160(2), 117-134.
[http://dx.doi.org/10.1016/j.jconrel.2012.03.020] [PMID: 22484195]

Gabizon, A.; Shmeeda, H.; Barenholz, Y. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin. Pharmacokinet., 2003, 42(5), 419-436.
[http://dx.doi.org/10.2165/00003088-200342050-00002] [PMID: 12739982]

Wiesing, U.; Clausen, J. The clinical Research of Nanomedicine: A New Ethical Challenge? NanoEthics, 2014, 8, 19-28.
[http://dx.doi.org/10.1007/s11569-014-0191-0]

Resnik, D.B.; Tinkle, S.S. Ethical issues in clinical trials involving nanomedicine. Contemp. Clin. Trials, 2007, 28(4), 433-441.
[http://dx.doi.org/10.1016/j.cct.2006.11.001] [PMID: 17166777]

Hofmann-Amtenbrink, M.; Grainger, D.W.; Hofmann, H. Nanoparticles in medicine: Current challenges facing inorganic nanoparticle toxicity assessments and standardizations. Nanomedicine (Lond.), 2015, 11(7), 1689-1694.
[http://dx.doi.org/10.1016/j.nano.2015.05.005] [PMID: 26051651]

Anselmo, A.C.; Mitragotri, S. Nanoparticles in the clinic. Bioeng. Transl. Med., 2016, 1(1), 10-29.
[http://dx.doi.org/10.1002/btm2.10003] [PMID: 29313004]

Anselmo, A.C.; Mitragotri, S. Nanoparticles in the clinic: An update. Bioeng. Transl. Med., 2019, 4(3), e10143.
[http://dx.doi.org/10.1002/btm2.10143] [PMID: 31572799]

Fatehi, L.; Wolf, S.M.; McCullough, J.; Hall, R.; Lawrenz, F.; Kahn, J.P.; Jones, C.; Campbell, S.A.; Dresser, R.S.; Erdman, A.G.; Haynes, C.L.; Hoerr, R.A.; Hogle, L.F.; Keane, M.A.; Khushf, G.; King, N.M.P.; Kokkoli, E.; Marchant, G.; Maynard, A.D.; Philbert, M.; Ramachandran, G.; Siegel, R.A.; Wickline, S. Recommendations for nanomedicine human subjects research oversight: an evolutionary approach for an emerging field. J. Law Med. Ethics, 2012, 40(4), 716-750.
[http://dx.doi.org/10.1111/j.1748-720X.2012.00703.x] [PMID: 23289677]

Gordijn, B. Nanoethics: from utopian dreams and apocalyptic nightmares towards a more balanced view. Sci. Eng. Ethics, 2005, 11(4), 521-533.
[http://dx.doi.org/10.1007/s11948-005-0024-1] [PMID: 16279753]

Bawa, R. FDA and nanotech: baby steps lead to regulatory uncertainty.Bio-Nanotechnology; Blackwell Publishing Ltd.: Oxford, UK, 2013, pp. 720-732.
[http://dx.doi.org/10.1002/9781118451915.ch41]

Bawarski, W.E.; Chidlowsky, E.; Bharali, D.J.; Mousa, S.A. Emerging nanopharmaceuticals. Nanomedicine (Lond.), 2008, 4(4), 273-282.
[http://dx.doi.org/10.1016/j.nano.2008.06.002] [PMID: 18640076]

De Jong, W.H.; Borm, P.J.A. Drug delivery and nanoparticles:applications and hazards. Int. J. Nanomedicine, 2008, 3(2), 133-149.
[http://dx.doi.org/10.2147/IJN.S596] [PMID: 18686775]

Farjadian, F.; Ghasemi, A.; Gohari, O.; Roointan, A.; Karimi, M.; Hamblin, M.R. Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities. Nanomedicine (Lond.), 2019, 14(1), 93-126.
[http://dx.doi.org/10.2217/nnm-2018-0120] [PMID: 30451076]